Van Allen et al. correlated genomic and transcriptomic data with response to CTLA4 blockade [50] while Hugo et al. with response to anti-PD1 therapy [51], both using metastatic melanoma samples collected prior to immunotherapy treatment. This evidence concerns the gene PDCD1 and metastatic melanoma.